Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

This publication has 30 references indexed in Scilit:

• Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
  European Journal Of Cancer, 2005
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
  The Lancet, 2004
• Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
  European Journal Of Cancer, 2004
• The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
  Angiogenesis, 2004
• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
  Journal of Clinical Oncology, 2003
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584
  Seminars in Oncology, 2003
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
  Science, 2003
• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
  Science, 1998